Sign In
Buy GPCR
$48.04
-1.43 (-2.89%)
At Close: Jul 31, 2026
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
06:00am, Tuesday, 04'th Jun 2024
Undervalued biotech stocks can offer some of the most explosive opportunities. That is, if you can spot the right one at the right time.
Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz
06:27pm, Monday, 03'rd Jun 2024
Jared Holz, Mizuho, joins 'Fast Money' to talk Structure Therapeutics soaring on its GLP-1 data and M&A targets in the obesity drug space.
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
04:09pm, Monday, 03'rd Jun 2024
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met
Structure Therapeutics (GPCR) Stock Soars 60% on Weight Loss Drug Success
03:30pm, Monday, 03'rd Jun 2024
Structure Therapeutics (NASDAQ: GPCR ) stock is surging today, up 60% after the biotech company reported promising results of its mid-stage trials for its weight loss pills. Indeed, after 12 weeks, pa
Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results
01:42pm, Monday, 03'rd Jun 2024
Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug.
Structure Therapeutics' stock jumps on weight-loss-pill trial results
08:42am, Monday, 03'rd Jun 2024
Structure Therapeutics Inc.'s American depositary receipts GPCR, +1.30% gained more than 6% premarket on Monday after the company said its experimental weight-loss pill achieved its aims in a clinical
GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p
Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing
06:00am, Friday, 31'st May 2024
Sometimes the next big thing stocks to buy and hold are flying well under the radar. Look at Apple (NASDAQ: AAPL ).
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
10:34am, Thursday, 09'th May 2024
Investors are well aware of the explosive growth potential in weight loss drug stocks. That growth began last year with Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ).
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
11:33am, Tuesday, 07'th May 2024
Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
06:33am, Wednesday, 24'th Apr 2024
Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ). So-called GLP-1 receptor agonists represent a funda
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
07:09pm, Tuesday, 16'th Apr 2024
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
7 Small-Cap Stocks that Wall Street Loves for Good Reason
09:37am, Saturday, 30'th Mar 2024
With the major indexes at or near record highs, it's been easy to overlook the performance of the small-cap Russell-2000 Index. While the index is “only” up about 5% in 2024, it's up 21% in the pa
Wegovy and Zepbound Are King. Who's Coming for Their Crowns.
02:30am, Saturday, 09'th Mar 2024
Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
04:05pm, Friday, 08'th Mar 2024
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me
